User:Mr. Ibrahem/Cabozantinib
From Wikipedia, the free encyclopedia
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.[8][3] It is used in advanced disease or cases which have failed other treatments.[3] It is taken by mouth.[3]
![]() | |
Clinical data | |
---|---|
Pronunciation | ka" boe zan' ti nib[1] |
Trade names | Cometriq, Cabometyx, others |
Other names | XL184, BMS907351 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613015 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor[3] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ≥99.7% |
Metabolism | Liver (CYP3A4-mediated) |
Elimination half-life | 110 hours |
Excretion | Feces (54%), urine (27%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C28H24FN3O5 |
Molar mass | 501.514 g·mol−1 |
3D model (JSmol) | |
| |
|
Common side effects include diarrhea, tiredness, high blood pressure, nausea, and weight loss.[3] Other side effects may include bleeding, fistula, blood clots, liver problems, and reversible posterior leukoencephalopathy syndrome.[3] Use in pregnancy may harm the baby.[3] It is a tyrosine kinase inhibitor of MET, VEGFR, and AXL.[3]
Cabozantinib was approved for medical use in the United States in 2012 and Europe in 2014.[3][8] In the United Kingdom a dose of 60 mg a day for a month costs about £5,150 as of 2021.[10] This amount in the United States costs about 22,600 USD.[11]